The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study

Genetic Susceptibility Study of Primary Pulmonary Lymphoepithelioma-like Carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06801977

Acronym

CPLCC

Enrollment

10000

Registered

2025-01-30

Start date

2002-01-01

Completion date

2030-12-31

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Pulmonary Lymphoepithelioma-like Carcinoma

Keywords

Genome-Wide Association Study, primary Pulmonary Lymphoepithelioma-like Carcinoma

Brief summary

This retrospective case-control study aims to investigate the genetic mechanisms of primary Pulmonary Lymphoepithelioma-like Carcinoma, identify genetic susceptibility loci associated with its onset, and explore potential pathogenic genes, providing new insights for its etiological research.

Detailed description

Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare non-small cell lung cancer (NSCLC) that histologically resembles nasopharyngeal carcinoma (NPC) and predominantly affects the Asian population. Epstein-Barr virus (EBV) infection is a recognized pathogenic factor, and the regional prevalence of pLELC suggests that genetic susceptibility also plays an important role. However, no genetic studies on pLELC have been conducted, leaving its genetic etiology poorly understood. In this study, genotyping for all the subjects was performed by using Illumina Infinium Global Screening Array. Genome-wide association followed by meta-analysis was performed for pLELC cases and healthy controls. The primary objective of this study is to discover susceptibility genes that explain the genetic mechanisms of pLELC.

Interventions

GENETICGenome-wide genotyping

Whole blood from the participants was used to extract DNA for genotyping.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Case: Inclusion criteria: The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma.

Exclusion criteria

The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease. Controls: Inclusion criteria: The subject is in good physical condition and has a stable level of consciousness;

Design outcomes

Primary

Measure	Time frame	Description
the occurrence of Pulmonary Lymphoepithelioma-like Carcinoma	The enrollment of the participants	pathological diagnosis of Pulmonary Lymphoepithelioma-like Carcinoma

Countries

China

Contacts

Primary ContactWei-Hua Jia, MD

jiawh@sysucc.org.cn86+020-87342327

Backup ContactTong-Min Wang, PhD

wangtm@sysucc.org.cn86+020-87342410

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026